

# Prise en charge péri-opératoire des patients bénéficiant d'une chirurgie hépatique et/ou présentant une hépatopathie



Gabriel THIERRY

Présentation SAC 05/2024

# CHIRURGIE HÉPATIQUE = CHALLENGE

- ▶ Chirurgie digestive majeure
- ▶ Challenge hémorragique
- ▶ Challenge hémodynamique
- ▶ Challenge métabolique



# RÉHABILITATION AMÉLIORÉE



## Recovery after laparoscopic colonic surgery with epidural analgesia, and early oral nutrition and mobilisation




L. Bardram, P. Funch-Jensen, P. Jensen, M. E. Crawford, H. Kehlet

*Lancet* 1995; **345**: 763

The first two patients in the programme were not discharged until day 3, despite having normal bowel function on day 2, because of logistic or personal problems. The next six patients followed the scheduled plan and went home on the 2nd postoperative day. 1 month postoperatively all patients were back to normal function. They were very satisfied with the entire perioperative course and all would recommend the procedure to others; no one felt they had been discharged too early.

# RÉHABILITATION AMÉLIORÉE





# RÉHABILITATION AMÉLIORÉE

# ERAS<sup>®</sup> Society

World J Surg (2023) 47:11–34  
<https://doi.org/10.1007/s00268-022-06732-5>



SCIENTIFIC REVIEW

## **Guidelines for Perioperative Care for Liver Surgery: Enhanced Recovery After Surgery (ERAS) Society Recommendations 2022**



# Notre protocole



1. Written and oral patient information was provided by an anaesthetist at the time of the preoperative visit.
2. Fasting was as short as possible (6 hours for food, 2 hours for fluids expected)
3. Preoperative carbohydrate load 2-hour before induction of anaesthesia (except in case of insulin requiring diabetes mellitus or known gastroparesis)
4. Preoperative oral immunonutrition or nutrition therapy only if indicated.
5. No sedative premedication
6. Respect of antibioprohylaxis
7. Prevention of perioperative hypothermia
8. Laparoscopic approach
9. Locoregional anaesthesia (transversus abdominis plane block only)
10. Intravenous fluid and noradrenaline titrated using goal-directed-therapy.
11. Prevention of postoperative nausea and vomiting

12. Absence of abdominal drain
13. Absence or withdrawal of nasogastric tube at the end of surgery
14. Absence or withdrawal of urinary catheter at the end of surgery
15. Peroperative infusion of corticoids (dexamethasone)
16. Thromboprophylaxis
17. Early mobilisation (first 24h postoperative hours) with the help of a physiotherapist
18. Early oral intake (first 24h postoperative hours)
19. Multimodal peroperative analgesia (at least 3 modalities)
20. Multimodal postoperative analgesia (at least 3 modalities)
21. Use of anti-inflammatory drugs

# IMPACT DE LA RÉHABILITATION AMÉLIORÉE SUR LA MORBIDITÉ POSTOPÉRATOIRE



# Impact of enhanced recovery program implementation on postoperative outcomes after liver surgery.


## A monocentric retrospective study

Implementation of an enhanced rehabilitation protocol in liver surgery in December 2020

Application of 21 items Based on ERAS recommendations

Labeling of our hospital through an annual audit by the GRACE association

2 cohorts of 75 patients (before and after ERP implementation)





# DÉNUTRITION

Identifier et traiter une dénutrition → ↘ morbidité postop



- ▶ Chirurgie oncologique colorectale : 1/3
- ▶ Chirurgie oncologique upper-gastrointestinal : 1/2





**ESPEN**

European Society for Clinical Nutrition and Metabolism

- *Peri- or at least postoperative administration of specific formula enriched with immunonutrients (arginine, omega-3-fatty acids, ribonucleotides) should be given in malnourished patients undergoing **major cancer surgery** (Recommendation B).*
- *There is currently no clear evidence for the use of these formulae enriched with immunonutrients vs. standard oral nutritional supplements exclusively in the preoperative period (Recommendation 0).*




*Consensus (89% agreement)*

# ANALGÉSIE MULTIMODALE




ERAS item	Summary	Evidence level	Grade of recommendation
12. Minimally invasive surgery	In trained teams and when clinically appropriate, laparoscopic liver resection is recommended since it reduces postoperative length of stay and complication rates.	Moderate	Strong
13. Epidural, postoperative intravenous, and postoperative per oral analgesia	For open liver surgery, thoracic epidural analgesia can provide excellent analgesia but has significant disadvantages. In fact, optimal postoperative management is key to avoid hypotension and mobility issues which can be detrimental to rapid recovery. Multimodal analgesia (including potential use of intrathecal opiates) is recommended.	High	Strong
	Regarding laparoscopic surgery, there is no need for regional anesthesia techniques, as multimodal analgesia combined with judicious intravenous opiates provides functional analgesia.	Low	Weak

# ANESTHÉSIE LOCORÉGIONALE







**a** Right hemihepatectomy




**b** Extended right hemihepatectomy



**c** Left lateral liver resection




**d** Left hemihepatectomy







**a** Right hemihepatectomy





**b** Extended right hemihepatectomy



**c** Left lateral liver resection



**d** Left hemihepatectomy



**Benchmark : 3.0 jours**

Benchmark = durée maximale de séjour des 25% de dossiers ayant les durées les plus courtes.

**MES STATISTIQUES**

Durée médiane réelle de séjour : **2.0 jours** (écart interquartile : **4.0 jours**)

Durée médiane théorique\* de séjour : **2.0 jours** \* durée au bout de laquelle tous les critères de sortie étaient réunis

Taux de réadmission dans le premier mois : **14.3 %**


**ENSEMBLE DES CENTRES GRACE**

Durée médiane réelle de séjour : **5.0 jours** (écart interquartile : **4.0 jours**)


Durée médiane théorique de séjour : **5.0 jours**

Taux de réadmission dans le premier mois : **5.0 %**


**a Right hemihepatectomy**





**b Extended right hemihepatectomy**



**c Left lateral liver resection**



**d Left hemihepatectomy**



**Benchmark : 3.0 jours**

Benchmark = durée maximale de séjour des 25% de dossiers ayant les durées les plus courtes.

**MES STATISTIQUES**

Durée médiane réelle de séjour : **2.0 jours** (écart interquartile : **4.0 jours**)

Durée médiane théorique\* de séjour : **2.0 jours** \* durée au bout de laquelle tous les critères de sortie étaient réunis


Taux de réadmission dans le premier mois : **14.3 %**

**ENSEMBLE DES CENTRES GRACE**

Durée médiane réelle de séjour : **5.0 jours** (écart interquartile : **4.0 jours**)

Durée médiane théorique de séjour : **5.0 jours**

Taux de réadmission dans le premier mois : **5.0 %**



# LIDOCAÏNE ET HÉPATECTOMIE

## Lidocaine HCl<sub>Systemic</sub>

Xylocaine®



### ❖ Ventricular Arrhythmia

- **Stable VT:** 1-1.5 mg/kg IV/IO + 0.5-0.75 mg/kg Q5-10min; 1-4 mg/min infusion after rhythm corrected
- **Pulseless VT/VF:** 1-1.5 mg/kg IV/IO + 0.5-0.75 mg/kg Q5-10min; 1-4 mg/min infusion after return of perfusion

### ❖ Status Epilepticus

- **Off-label:** 1 mg/kg IV, wait 2 min then 0.5 mg/kg IV, then 30 µg/kg/min continuous IV



### Arrhythmia

### Cardiovascular Depression

Respiratory Depression

Audiovisual Disturbance

Dizziness/Seizures

Malignant Hyperthermia

Methemoglobinemia

Lethargy/Nausea (common)



### Lidocaine Hypersensitivity

Amide Anesthetic HS

Adams-Stokes

WPW

Severe SA/AV/IV Block




Pregnancy Category B

## Voltage-Gated Sodium Channel Blocker



Lidocaine



Na<sup>+</sup> Conduction Inhibited

↓ AP Initiation & Propagation

Cardiac & Neuronal Membranes Stabilized



**Hepatic Metabolism**, Active Metabolites  
CYP1A2/3A4 Substrate, CYP2D6 Inhibitor


½-Life: 1.5-2h

Renal Excretion



\$4.59/50 mL 1% lidocaine vial (Generic)


# LIDOCAÏNE ET HÉPATECTOMIE MAJEURE



## Source

Safety of perioperative intravenous lidocaine in liver surgery – A pilot study

Journal of Anaesthesiology  
Clinical Pharmacology : April 08,  
2024



Perioperative Medicine | January 2023

## Lidocaine Intraoperative Infusion Pharmacokinetics during Partial Hepatectomy for Living Liver Donation ✓

Cara E. Crouch, M.D.; Barbara J. Wilkey, M.D.; Adrian Hendrickse, B.M., F.R.C.A.; Alexander M. Kaizer, Ph.D.; Björn Schniedewind, B.S.; Uwe Christians, M.D., Ph.D.; Thomas K. Henthorn, M.D.; Ana Fernandez-Bustamante, M.D., Ph.D.

+ Author and Article Information

*Anesthesiology* January 2023, Vol. 138, 71–81.

<https://doi.org/10.1097/ALN.0000000000004422>

## Conclusions

Intravenous lidocaine infusions are an acceptable option for multimodal pain management in patients undergoing a hepatectomy for living donation if the lidocaine infusion is stopped when the liver resection is complete. Clearance of lidocaine is decreased proportionally to the remaining liver mass, which should guide lidocaine infusion administration or dosing adjustments for patients undergoing liver resection surgery.



# AINS ET HÉPATECTOMIE

REVIEW ARTICLE: PDF ONLY

## Controversies in the Perioperative Use of Nonsteroidal Antiinflammatory Drugs

Souter, Andrew J. MBChB, FRCA; Fredman, Brian MBBCh; White, Paul F. PhD, MD, FFARACS

Author Information

*Anesthesia & Analgesia* 79(6):p 1178-1190, December 1994.

### Systematic Review and Meta-Analysis of the Association Between Non-Steroidal Anti-Inflammatory Drugs and Operative Bleeding in the Perioperative Period

Opioid Crisis has led to Need for Increased use of Non-steroidal Anti-inflammatory Drugs (NSAIDs) in the Perioperative Period



Concern for bleeding prevents uptake

Searched 2,536 articles  
74 manuscripts included  
1987-2019



151,031 patients over a wide range of specialties



Three types of complications




- \*Hematoma\*
- \*Operating Room Takeback\*
- \*Blood Transfusions\*

No evidence of significant difference in risk for complications in NSAID versus non-NSAID groups



# ACIDE TRANEXAMIQUE

## Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis

 OPEN ACCESS

World J Surg (2022) 46:441–449  
<https://doi.org/10.1007/s00268-021-06355-2>

World Journal  
of Surgery



SCIENTIFIC REVIEW

### Safety and Efficacy of Tranexamic Acid to Minimise Perioperative Bleeding in Hepatic Surgery: A Systematic Review and Meta-Analysis

BMJ

BMJ 2012;344:e3054 doi: 10.1136/bmj.e3054 (Published 21 May 2012)

<http://dx.doi.org/10.1016/j.hpb.2016.09.005>

HPB

ORIGINAL ARTICLE

### Major liver resection, systemic fibrinolytic activity, and the impact of tranexamic acid

**Conclusions:** There is no thromboelastographic evidence of hyperfibrinolysis in patients undergoing major liver resection. TXA does not influence the change in systemic fibrinolysis; it may reduce bleeding through a different mechanism of action.

# ACIDE TRANEXAMIQUE

ANAESTHESIA

## Oral as compared to intravenous tranexamic acid to limit peri-operative blood loss associated with primary total hip arthroplasty

### A randomised noninferiority trial

Piette, Nicolas; Beck, Florian; Carella, Michele; Hans, Gregory; Maesen, Didier; Kurth, William; Lecoq, Jean-Pierre; Bonhomme, Vincent L.

Author Information 

*European Journal of Anaesthesiology* 41(3):p 217-225, March 2024. | DOI: 10.1097/EJA.0000000000001950

**Biodisponibilité de 50%**

**Posologie préopératoire H-2 :2gr (4 cp de 500mg)**

# GESTION DE LA VENTILATION

**EJA**


*Eur J Anaesthesiol* 2016; **33**:292–298

## ORIGINAL ARTICLE

### The effects of intraoperative lung protective ventilation with positive end-expiratory pressure on blood loss during hepatic resection surgery

*A secondary analysis of data from a published randomised control trial (IMPROVE)*

Arthur Neuschwander, Emmanuel Futier, Samir Jaber, Bruno Pereira, Mathilde Eurin, Emmanuel Marret, Olga Szymkewicz, Marc Beaussier and Catherine Paugam-Burtz





# MANŒUVRES DE PRINGLE


- Préconditionnement ischémique (5 min)  
Puis phases de 15-20 min  
5 min de déclampage entre chacune

- Variations hémodynamiques

BJA: *British Journal of Anaesthesia*, Volume 93, Issue 2, August 2004.  
<https://doi.org/10.1093/bja/ae1195>



- Hyperglycémies +++



The American Journal of Surgery  
Volume 199, Issue 1, January 2010, Pages 8-13



# GESTION DE LA VOLEMIE = GOAL DIRECTED FLUID THERAPY



General Guidelines for  
**Goal-directed therapy in ER**

### Preoperatively

**#1** Minimize NPO! clear CHO-containing liquids (preferably complex) up to 2 hours before surgery

**#2** If bowel preparation is performed, iso-osmotic agents are preferred

**#3** Risk stratification based on available and validated surgical risk calculators (e.g. NSQIP, SORT)

### Intraoperatively

**Low risk**: Standard monitoring and integration of clinical data / situational awareness

**Medium risk**: Is there a problem? (no/yes)

**High risk**: Fluid responsiveness, Stroke volume, cardiac output, and fluid responsiveness

Reverse the PROBLEM



Maintenance fluid @ 1-4 ml kg<sup>-1</sup> h<sup>-1</sup> (PBW) while avoiding large deviations from "zero balance"

### Immediately postoperatively (0-12h)

i.v. fluids (1 ml kg<sup>-1</sup> h<sup>-1</sup> on a pump) initially, immediate oral intake as tolerated (discontinue i.v. when tolerating PO). Continue the intraoperative strategy to if possible (especially in medium and high risk patients)

### Later postoperatively (> 12h)

DRink, Eat, Analgesia, Move, Sleep





REVIEW ARTICLE

# Central venous pressure and liver resection: a systematic review and meta-analysis

Michael J. Hughes, Nicholas T. Ventham, Ewen M. Harrison & Stephen J. Wigmore

Department of Clinical Surgery, Royal Infirmary of Edinburgh, Edinburgh, UK



All surgeries  
Low PVC =  $\nabla$  EBL  
but same morbidity

ORIGINAL ARTICLE

# Goal-directed fluid therapy vs. low central venous pressure during major open liver resections (GALILEO): a surgeon- and patient-blinded randomized controlled trial

Iris M. Jongerius<sup>1,\*</sup>, Timothy H. Mungroop<sup>1,2\*</sup>, Zühre Uz<sup>2</sup>, Bart F. Geerts<sup>1</sup>, Rogier V. Immink<sup>1</sup>, Martin V.H. Rutten<sup>1</sup>, Markus W. Hollmann<sup>1</sup>, Thomas M. van Gulik<sup>2</sup>, Marc G. Besselink<sup>2</sup> & Denise P. Veelo<sup>1</sup>

<sup>1</sup>Amsterdam UMC, University of Amsterdam, Department of Anesthesiology, and <sup>2</sup>Amsterdam UMC, University of Amsterdam, Department of Surgery, Cancer Center Amsterdam, Meibergdreef 9, Amsterdam, the Netherlands

Major, Open. GDFT = EBL and morbidity

# GESTION DE LA GLYCÉMIE

-> CHARGE GLUCIDIQUE PRÉOPÉRATOIRE


- **400 ml le matin de l'intervention : G12,5% ou jus de pomme/oasis**
- ↓ Résistance à l'insuline postopératoire  
(*Multicentric RCT 662 p : Ann Surg 2018*)
- ↓ DMS en chirurgie abdominale majeure  
(3 MT 2013-17 1500-3000 p : Brit J surg)
- Amélioration du confort patient



Pas de diminution des taux de complications postopératoires

# ANESTHÉSIE ET CHIRURGIE CHEZ LE CIRRHOTIQUE = CHALLENGE

- ▶ Patient à risque élevé
- ▶ Challenge hémorragique
- ▶ Challenge analgésique
- ▶ Challenge métabolique



# PRISE EN CHARGE (PRÉ)PÉRIOPÉRATOIRE

## ↗ morbidity :

- ❖ ↗ **complications infectieuses**
  - ❖ ↗ taux de transfusion
  - ❖ ↗ décompensation cardiaque
  - ❖ ↗ décompensation œdémato-ascitique
- 
- ▶ Evaluer la gravité de l'hépatopathie
    - ▶ Anticiper les risques liés à la chirurgie
      - ▶ Corriger ce qui peut l'être
      - ▶ Adapter notre anesthésie

# MELD (MODEL FOR END-STAGE LIVER DISEASE)

➤ Patrick Kamath : 2001


➤  $3,78 \times \ln(\text{bilirubinémie mg/dL})$

$+ 1,12 \times \ln(\text{INR})$

$+ \ln(\text{créatininémie mg/dL}) + 6,43$

➤ 2016 : ajout de la valeur de Na sérique = MELD-Na Score

➤ Si dialyse 2x/semaine : créatininémie encodée 4 mg/dL






# EN PRATIQUE

- ▶ Si MELD  $\leq$  **8** : Risque de morbidité périopératoire faible
- ▶ Si MELD **9 - 14** : Risque de morbidité périopératoire élevé  
Indication chirurgicale prudente
- ▶ Si MELD  $\geq$  **15** : Intervention non vitale contre-indiquée

# CIRRHOSE ET HÉMOSTASE

- ↘ Synthèse facteurs de coagulation
- facteurs inhibiteurs
- protéines de la fibrinolyse



↗ INR      ≠      ↗ ~~risque hémorragique~~  
=      ↗ degré de sévérité de la cirrhose

**Thrombopénie (+ thrombopathie) et afibrinogénémie = ↗ risque hémorragique**

▶ En pratique (empirique, efficacité non prouvée) :


**Plaquettes pour taux > 50.000**

**PFC (15 mL/kg) si Quick < 50% (INR 1,6) ou TCA ≥ + 4 sec**

**Fibrinogène 30mg/kg si saignement et fibri < 1,5 g/L**

# PRÉHABILITATION

- ▶ Kinésithérapie préopératoire
- ▶ Sevrage OH (4 semaines)
- ▶ Prise en charge pluridisciplinaire :
  - Optimisation du traitement (diurétiques, ponction ascite,...)
  - Bilan/Suivi nutritionnel
  - Suivi psychologique -> Sevrage
  - Bilan globale : ETT, gastroscopie



The influence of prehabilitation in patients with liver cirrhosis before liver transplantation: a randomized clinical trial

Lubomír SKLADANÝ<sup>1,2</sup>, Dávid LIŠKA<sup>3\*</sup>, Daniel GURÍN<sup>4</sup>, Pavol MOLČAN<sup>1</sup>,  
Roman BEDNÁR<sup>5</sup>, Janka VNENČÁKOVÁ<sup>1</sup>, Tomáš KOLLER<sup>6</sup>

# ÉTAT NUTRITIONNEL ET CIRRHOSE

## ► Cirrhose → Dénutrition fréquente

60% des patients cirrhotiques Child-Pugh C



Identifier et traiter une dénutrition en préop → ↘ morbidité postop

- ✓ Diagnostic à la consultation préop
- ✓ Renutrition préopératoire (SNO/*immunonut*)
- ✓ Postposer l'intervention si besoin (7j préop minimum)
- ✓ Hospitaliser pour prise en charge nutritionnelle si indiquée

# Diagnostic de dénutrition et cirrhose

- ▶ Oublier les protéines sériques (albumine, préalbumine)
- ▶ Rester critique face au BMI (œdème, ascite)

- ▶ Le mieux :

La calorimétrie

Estimation radiologique de la sarcopénie


→ *Difficile en pratique clinique*

Rechercher :

**BMI < 20 / Perte de poids > 10% / ↘ Apports**



# MÉTABOLISME HÉPATIQUE ET CIRRHOSE



S'y ajoutent les conséquences de la cirrhose :

Hypoalbuminémie –  $\searrow$  liaison protéique,  $\nearrow$  fraction libre

Hypertension portale  $\rightarrow$  shunt porto-systémique  $\rightarrow$   $\searrow$  1<sup>er</sup> passage hépatique

# PHARMACOLOGIE ET CIRRHOSE

▶ **Child-Pugh A** : pharmacocinétique presque inchangée


▶ **Child-Pugh B/C** :

- ▶ ↘ excrétion biliaire
- ▶ ↗ fraction libre
- ▶ ↗ biodisponibilité



↗ **potentiel d'action, toxicité et risque de surdosage**

# BENZODIAZÉPINES



Pathogenetic mechanisms of hepatic encephalopathy  
*Gut*  
Haussinger, D; Schliess, F  
Vol. 57 Issue 8, pp. 1156-1165, 2008.

Clinical Investigation

## Pharmacokinetic properties of remimazolam in subjects with hepatic or renal impairment


BJA  
British Journal of Anaesthesia



British Journal of Anaesthesia  
Volume 127, Issue 3, September 2021, Pages 415-423



## Remimazolam ?



# PARACETAMOL ET CIRRHOSE


*Gut*, 1988, 29, 1153–1157

*Liver and biliary*

## Glutathione deficiency in alcoholics: risk factor for paracetamol hepatotoxicity

B H LAUTERBURG AND MARIA E VELEZ


From the Department of Clinical Pharmacology, University of Berne, Switzerland and Center for Experimental Therapeutics and Department of Psychiatry, Baylor College of Medicine, Houston, Texas, USA



Research article

## The effect of acetaminophen (four grams a day for three consecutive days) on hepatic tests in alcoholic patients – a multicenter randomized study

EK Kuffner<sup>1</sup>, JL Green<sup>1</sup>, GM Bogdan<sup>1</sup>, PC Knox<sup>2</sup>, RB Palmer<sup>1</sup>, K Heard<sup>1</sup>, JT Slattery<sup>3</sup> and RC Dart\*<sup>1</sup>




**Figure 2**

Incidence of alanine aminotransferase (ALT) measures greater than three times upper limit of normal throughout study by treatment group.


dose APAP (650 mg twice per day, <1 week) is likely safe in patients with compensated cirrhosis. These data provide a foundation for future studies to test higher doses, longer treatment, and subjects who are decompensated, especially in light of the remarkably delayed adduct clearance in subjects with cirrhosis. (*Hepatology Communications* 2022;6:361–373).



# HÉMODYNAMIQUE : PROFIL PARTICULIER



« **HYPER  
DEBIT** »





# ATTEINTE PULMONAIRE

- ▶ Ascite volumineux/Epanchements pleuraux → **Syndrome restrictif**
- ▶ NO → Vasodilatation pulmonaire = **Syndrome hépato-pulmonaire**
- ▶ Circulation veino-veineuse → **Effet shunt**



## Mismatch V/Q

- ▶ Stade le plus avancé de la maladie : **Hypertension porto-pulmonaire (HTAP)** contre-indication à toute chirurgie non vitale  
→ Prise en charge complexe/Référer au pneumologue

**!!! Les recruter !!!**

Plusieurs études prouvent que des valeurs de PEEP allant jusque 10mmHg ne majorent pas le risque de saignement périopératoire et n'altèrent pas la vascularisation hépatique

*merci!*